title: Systematic analytical validation of commercial kits for the determination of novel biomarkers for clinical drug development.
abstract: The use of biomarkers during clinical drug-development programs may expedite pipeline decision making by adding critical information about the pharmacological mechanism and efficacy of a potential therapeutic agent. Currently, advice for laboratorians conducting method development and analytical validation of biomarker methods is provided by published White Paper recommendations from industry thought leaders. The adaptation of commercial test kits to generate biomarker data to support regulated studies offers unique challenges and limitations. In this perspective, we address these issues, including factors to consider when identifying a kit manufacturer and adapting commercial test kits for use in regulated studies. We offer a logical and systematic approach for defining the extent of analytical validation needed for application of commercial kits based upon the intended use of the biomarker data.
authors.affiliation: CEDRA Corporation, 8609 Cross Park Drive, Austin, TX 78660, USA. wnowatzke@cedracorp.com
authors.forename: William
authors.initials: W
authors.lastname: Nowatzke
authors.forename: Thomas G
authors.initials: TG
authors.lastname: Cole
authors.forename: Ronald R
authors.initials: RR
authors.lastname: Bowsher
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000032:analysis; D019963:Clinical Chemistry Tests / Q000295:instrumentation*; D019411:Clinical Laboratory Techniques; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D015203:Reproducibility of Results
chemical_list: D015415:Biomarkers